Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema

International Journal of Retina and Vitreous - Tập 8 Số 1
Hooshang Faghihi1, Bahman Inanloo1, Arash Mirzaee1, Kaveh Fadakar1, Ahmad Mirshahi1, Nazanin Ebrahimiadib1, Fariba Ghassemi1, Fatemeh Bazvand1, Abdulrahman Amini1, Masoud Mirghorbani1, Shahin Faghihi1, Elias Khalili Pour1, Hamid Riazi-Esfahani1
1Retina Service, Farabi Eye Hospital, Tehran University Of Medical Sciences, Qazvin Square, South Karegar Street, Tehran, 1336616351, Iran

Tóm tắt

Abstract Background To evaluate the additive effect of topical or sub-tenon injection of interferon (IFN)-α 2b in the treatment of refractory diabetic macular edema. Methods In this prospective study patients with center-involved DME who were unresponsive to 3 monthly consecutive IVB injections were recruited. Patients were divided into three groups: group1, received IFN- α 2b topical drop at a dose of 1mIU/ml four times a day for 3 months. Group 2, received a single sub-tenon injection of 1mIU/ml IFN- α 2b at the enrollment. Group 3 received artificial tears four times a day for 3 months (control group). All groups received three consecutive monthly IVB injections and were evaluated monthly up to 1 month following the last IVB injection. Results In this study, 59 eyes of 35 patients with refractory DME were assessed. The final follow-up showed that although CMT decreased in all groups, only patients in Group 2 had statistically significant lower CMT compared to their baseline values (change in CMT: − 117 ± 213 µm; p-value = 0.025). Comparison of CMT changes between three groups showed no statistically significant difference, although it was higher in group 2 (change in CMT: − 117 ± 213 µm (Group2) vs. − 49 ± 173 (Group 1) vs. − 36 ± 86 (Group 3); p-value = 0.085). Considering eyes with baseline CMT > 400 µm, sub-tenon injection of IFN α2b led to a significant reduction of CMT at the first month and final follow-up visit (CMT change: − 166 ± 210, − 145 ± 231 µm; p-value = 0.018 and 0.035, respectively). In this subgroup, eyes in Group 2 had lower CMT at the first month following treatment in comparison with the control group (CMT: 444 ± 123 µm vs. 544 ± 96 µm, p-value = 0.042). Alterations of CDVA were not statistically significant among groups, although patients in Group 1 had a significant improvement in vision at second and last follow up (CDVA change: − 0.23 ± 0.39, − 0.20 ± 0.43 logMAR; p-value = 0.030 and 0.010, respectively). Conclusions In short term, Sub-tenon injection of IFN might have an additive anatomical effect in eyes with refractory DME. Validation of this observation requires further prospective controlled studies.

Từ khóa


Tài liệu tham khảo

Li JQ, Welchowski T, Schmid M, Letow J, Wolpers C, Pascual-Camps I, et al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35:11–23. https://doi.org/10.1007/s10654-019-00560-z.

Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16:365–74. https://doi.org/10.1517/14712598.2016.1131265.

Ranchod TM, Fine SL. Primary treatment of diabetic macular edema. Clin Interv Aging. 2009;4:101–7. https://doi.org/10.2147/cia.s4357.

Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Investig Ophthalmol Vis Sci. 2001;42:2408–13.

Ebrahimiadib N, Lashay A, Riazi-Esfahani H, Jamali S, Khodabandeh A, Zarei M, et al. Intravitreal ziv-aflibercept in patients with diabetic macular edema refractory to intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retin. 2020;51:145–51.

Stefanini FR, Badaró E, Falabella P, Koss M, Farah ME, Maia M. Anti-VEGF for the management of diabetic macular edema. J Immunol Res. 2014;2014: 632307. https://doi.org/10.1155/2014/632307.

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222. https://doi.org/10.1159/000458539.

Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J. Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff. 2014;33:931–9. https://doi.org/10.1377/hlthaff.2013.0832.

Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol. 2011;89:709–17. https://doi.org/10.1111/j.1755-3768.2010.01918.x.

Torabi H. Management of refractory diabetic macular edema: a review article. Int J Med Rev. 2018;5:27–34. https://doi.org/10.29252/ijmr-050105.

Maleki A, Stephenson AP, Hajizadeh F. Topical interferon alpha 2b in the treatment of refractory diabetic macular edema. J Ophthalmic Vis Res. 2020;15:453–8. https://doi.org/10.18502/jovr.v15i4.7785.

Afarid M, Meshksar A, Salehi A, Safarpour MM. evaluation of the effect of topical interferon α2b as a complementary treatment of macular edema of patients with diabetic retinopathy: a double-blind placebo-controlled randomized clinical trial study. Retina. 2020;40:936–42. https://doi.org/10.1097/iae.0000000000002465.

George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135:44–53. https://doi.org/10.1016/j.pharmthera.2012.03.006.

Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129:288–94. https://doi.org/10.1001/archophthalmol.2011.3.

Shah SU, Kaliki S, Kim HJ, Lally SE, Shields JA, Shields CL. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on american joint committee on cancer classification. Arch Ophthalmol. 2012;130:159–64. https://doi.org/10.1001/archophthalmol.2011.385.

Sepulveda R, Pe’er J, Midena E, Seregard S, Dua HS, Singh AD. Topical chemotherapy for ocular surface squamous neoplasia: current status. Br J Ophthalmol. 2010;94:532–5. https://doi.org/10.1136/bjo.2009.160820.

Boehm MD, Huang AJW. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology. 2004;111:1755–61. https://doi.org/10.1016/j.ophtha.2004.01.034.

Cheung CMG, Vania M, Ang M, Chee SP, Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis. 2012;18:830–7.

Gillies MC, Su T. Interferon-α 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res. 1995;49:277–88. https://doi.org/10.1006/mvre.1995.1024.

Kawali A, Snehith R, Singh V, Sanjay S, Mahendradas P, Shetty R. Topical interferon—a novel treatment for pseudophakic macular edema. Indian J Ophthalmol. 2021;69:2355–60.

Kawali A, Sanjay S, Mohan A, Mahendradas P, Shroff S, Shetty R. Intensive topical interferon therapy in uveitic macular edema. Indian J Ophthalmol. 2022;70:2986–9.

Thomas AS, Lin P. Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2020;31:174–84.

Jung JL, Harasawa M, Patnaik JL, Palestine AG. Subtenon triamcinolone acetonide injection with topical anesthesia in pediatric non-infectious uveitis. Ophthalmol Ther. 2022;11:811–20.

Cellini M, Strobbe E, Balducci N, Campos E. Effect of subtenon injection of natural leucocytic interferon-α for treatment of age-related choroidal neovascularization. Acta Ophthalmol. 2011. https://doi.org/10.1111/j.1755-3768.2011.345.x.

Cellini M, Balducci N, Strobbe E, Campos EC. Subtenon injection of natural leukocyte interferon α-2a in diabetic macular edema: a case report. BMC Ophthalmol. 2013. https://doi.org/10.1186/1471-2415-13-63.

Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136:257–69.

Wallsh JO, Gallemore RP. Anti-vegf-resistant retinal diseases: a review of the latest treatment options. Cells. 2021;10:1049. https://doi.org/10.3390/cells10051049.

Chen YY, Chang PY, Wang JK. Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab: analysis of response to aflibercept. Asia Pac J Ophthalmol. 2017;6:250–5. https://doi.org/10.22608/apo.2016186.

Deuter CME, Gelisken F, Stübiger N, Zierhut M, Doycheva D. Successful treatment of chronic pseudophakic macular edema (Irvine-gass syndrome) with interferon alpha: a report of three cases. Ocul Immunol Inflamm. 2011;19:216–8. https://doi.org/10.3109/09273948.2011.562341.

Tanner V, Kanski JJ, Frith PA. Posterior sub-Tenon’s triamcinolone injections in the treatment of uveitis. Eye. 1998;12:679–85. https://doi.org/10.1038/eye.1998.168.

Cardillo JA, Melo LAS, Costa RA, Skaf M, Belfort R, Souza-Filho AA, et al. Comparison of intravitreal versus posterior sub-Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557–63. https://doi.org/10.1016/j.ophtha.2005.03.023.

Indraccolo S. Interferon-α as angiogenesis inhibitor: learning from tumor models. Autoimmunity. 2010;43:244–7. https://doi.org/10.3109/08916930903510963.

von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Öberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437–48. https://doi.org/10.1093/jnci/95.6.437.

Jin-Woo K, Jee D. Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment. PLoS ONE. 2018;13: e0203408. https://doi.org/10.1371/journal.pone.0203408.

Ferris FL, Maguire MG, Glassman AR, Ying GS, Martin DF. Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol. 2017;135:145–9. https://doi.org/10.1001/jamaophthalmol.2016.4820.

Thông tin
Thông tin xuất bản

International Journal of Retina and Vitreous

Tập 8 Số 1

Thông tin tác giả